13 In a safety analysis, TEAEs included diarrhea (48.8%), nausea (29.5% ... Data accumulated to date with respect to various PI3K inhibitors suggest improved response rates and longer survival ...
Medpage Today on MSN1 个月
PI3K Inhibitor Wins FDA Approval for Advanced Breast CancerThe FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi ... and creatinine; and stomatitis; diarrhea; fatigue; rash; ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈